Côte d'Ivoire Infrastructure Pharma

CFBANQUE Investment confirms the BBB rating assigned to Côte d'Ivoire Infrastructure Pharma (BNK1807.BC), an operator in the Infrastructure sector based in Côte d'Ivoire. This credit opinion reflects an investment-grade credit profile, with a satisfactory capacity to service its debt and absorb moderate sectoral shocks.

From a fundamental standpoint, the issuer posts an EBITDA margin of 51.8% which sits at the upper end of the sector range and evidences robust pricing power and exhibits a contained net leverage of 0.55x EBITDA, providing comfortable headroom to absorb capital expenditure and debt servicing. With revenues of $8.64B and a market capitalisation of $80M, Côte d'Ivoire Infrastructure Pharma commands a focused economic footprint within its domestic market.

Our proprietary models assign a Debt Capacity score of 788/1000, an Investment score of 729/1000 and an ESG & Governance score of 590/1000, reflecting a solid debt coverage, an attractive investment potential and ESG standards on a continuous improvement trajectory.

The Positive outlook reflects our expectation of a gradual improvement in the credit profile over a 12 to 18 month horizon, subject to the execution of the strategic plan communicated by the issuer. This analysis stems from the combined review of our quantitative models and the qualitative judgement of the CFBANQUE Investment rating committee, and may be updated in line with the evolution of fundamentals or the regional macroeconomic environment.